What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
The scientist’s investigation covers issues in Internal medicine, Cardiology, Myocardial infarction, Surgery and TIMI.
He works mostly in the field of Cardiology, limiting it down to topics relating to Magnetic resonance imaging and, in certain cases, Cardiomyopathy and Myocardial fibrosis, as a part of the same area of interest.
As a member of one scientific family, C. Michael Gibson mostly works in the field of Myocardial infarction, focusing on Angioplasty and, on occasion, Balloon, Reperfusion therapy and Angiography.
His work in the fields of Surgery, such as Randomized controlled trial and Mortality rate, overlaps with other areas such as Animal science and Oily fish.
He has included themes like Fibrinolysis, Fibrinolytic agent, Coronary circulation, Abciximab and Hemodynamics in his TIMI study.
His Percutaneous coronary intervention study incorporates themes from Stroke, Aspirin, Conventional PCI and Intensive care medicine.
His most cited work include:
- Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (4926 citations)
- Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium (2146 citations)
- Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. (1850 citations)
What are the main themes of his work throughout his whole career to date?
C. Michael Gibson mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Percutaneous coronary intervention and TIMI.
Internal medicine is often connected to Surgery in his work.
His Myocardial infarction study combines topics in areas such as Odds ratio, Randomized controlled trial and Coronary artery disease.
His work investigates the relationship between Percutaneous coronary intervention and topics such as Antithrombotic that intersect with problems in Intensive care medicine.
The TIMI study combines topics in areas such as Perfusion, Fibrinolysis, Fibrinolytic agent, Abciximab and Angina.
In his study, Hypertrophic cardiomyopathy is strongly linked to Heart disease, which falls under the umbrella field of ST elevation.
He most often published in these fields:
- Internal medicine (88.47%)
- Cardiology (77.69%)
- Myocardial infarction (59.90%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (88.47%)
- Cardiology (77.69%)
- Percutaneous coronary intervention (36.84%)
In recent papers he was focusing on the following fields of study:
C. Michael Gibson mostly deals with Internal medicine, Cardiology, Percutaneous coronary intervention, Myocardial infarction and Conventional PCI.
All of his Internal medicine and Acute coronary syndrome, Stroke, TIMI, Rivaroxaban and Randomized controlled trial investigations are sub-components of the entire Internal medicine study.
When carried out as part of a general Cardiology research project, his work on Coronary artery disease, Heart failure and P2Y12 is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Percutaneous coronary intervention research includes themes of Clopidogrel, Aspirin, Atrial fibrillation and Antithrombotic.
His Myocardial infarction research incorporates themes from Placebo and Cause of death.
His biological study spans a wide range of topics, including Clinical trial, Surgery and Incidence.
Between 2016 and 2021, his most popular works were:
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up (1132 citations)
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up (1132 citations)
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease (337 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Cardiology
His primary areas of study are Internal medicine, Percutaneous coronary intervention, Myocardial infarction, Cardiology and Antithrombotic.
His is involved in several facets of Internal medicine study, as is seen by his studies on Acute coronary syndrome, TIMI, Betrixaban, Stroke and Deep vein.
His Percutaneous coronary intervention research integrates issues from Clinical trial, Conventional PCI, Percutaneous, Atrial fibrillation and Aspirin.
C. Michael Gibson combines subjects such as Interquartile range, Discontinuation, Heart failure, Respiratory failure and Hazard ratio with his study of Myocardial infarction.
His study on Cardiology is mostly dedicated to connecting different topics, such as Placebo.
He has included themes like Meta-analysis, Regimen and Intensive care medicine in his Antithrombotic study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
